glp-1 receptor pharmacology
Oral Orforglipron Outpaces Semaglutide For The 3rd Time
56% of the current GLP-1 market is dominated by injectable tirzepatide, yet Orforglipron is the first non-peptide oral agent to surpass oral semaglutide in both A1C reduction and weight loss. In head-to-head studies it achieved greater glycemic control and deeper weight loss, signaling a new benchmark for oral metabolic therapy.